P53 protein is absent from the serum of patients with lung cancer

British Journal of Cancer

Volumn 74, Issue 9, 1996, Pages 1434-1440

  Levesque, M A ^a,b   D'Costa, M ^b,c   Diamandis, E P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Enzyme linked immunosorbent assay; Lung neoplasm; p53 protein; Tumour marker

Indexed keywords

CELL PROTEIN; HETEROPHILE ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; TUMOR SUPPRESSOR GENE;

EID: 0029828923     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.561     Document Type: Article

References (57)

1. ANGELOPOULOU K, DIAMANDIS EP, SUTHERLAND DJA, KELLEN JA AND BUNTING PS. (1994). Prevalence of serum antibodies against the p53 tumour suppressor gene protein in various cancers. Int. J. Cancer, 58, 480 487.
2. BARTER J, BARTKOVA J, VOJTESEK B, STASKOVA Z, LUKAS J, REJTHAR A, KOVARIK J, MIDGLEY CA, GANNON JV AND LANE DP. (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6, 1699 - 1703.
3. BARTKOVA J, BARTEK J, VOJTESEK B, LUKAS J, REJTHAR A, KOVARIK J, MILLIS RR, LANE DP AND BARNES DM. (1993). Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur. J. Cancer, 29A, 881 - 886.
4. BEAHRS OH, HENSON DE, HUTTER RVP AND KENNEDY BJ. (1992). Manual for Staging of Cancer, 3rd ed. pp. 115 - 119. JB Lippincott: Philadelphia.
5. BENNETT WP, COLBY TV, TRAVIS WD, BORKOWSKI A, JONES RT, LANE DP, METCALF RA, SAMET JM, TAKESHIMA Y, GU JR, VAHAKANGAS KH, SOINI Y, PAAKKO P, WELSH JA, TRUMP BF AND HARRIS CC. (1993). p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53, 4817 - 4822.
6. BORING CC, SQUIRES TS AND TONG T. (1993). Cancer statistics, 1993. CA Cancer J. Clin., 43, 7 - 26.
7. BOSCATO LM AND STUART MC. (1986). Incidence and specificity of interference in two-site immunoassays. Clin. Chem., 32, 1491 - 1495.
8. BRAMBILLA E, GAZZERI S, MORO D, CARON DE FROMENTEL C, GOUYER V, JACROT M AND BRAMBILLA C. (1993). Immunohistochemical study of p53 in human lung carcinomas. Am. J. Pathol., 143, 199 - 210.
9. BRAUN A, STRAIF K, KONIETZKO N, WIESNER B, LOEFFLER S, PRESEK P AND WOITOWITZ H-J. (1995). Detection of oncogene and tumor suppressor gene products in serum of former uranium miners for secondary prevention of radon-induced lung cancer. Clin. Chem., 41, 1913 - 1915.
10. CAAMANO J, RUGGERI B, MOMIKI S, SICKLER A, ZHANG SY AND KLEIN-SZANTO AJP. (1991). Detection of p53 in primary lung tumors and nonsmall cell carcinoma cell lines. Am. J. Pathol., 139, 839 - 845.
11. DIAMANDIS EP AND LEVESQUE MA. (1995). Assessment of p53 overexpression by non-immunohistochemical methods. J. Pathol., 175, 93 - 95.
12. DOSAKA-AKITA H, SHINDOH M, FUJINO M, KINOSHITA I, AKIE K, KATOH M AND KAWAKAMI Y. (1994). Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am. J. Clin. Pathol., 102, 660 - 664.
13. ESRIG D, ELMAJIAN D, GROSHEN S, FREEMAN JA, STEIN JP, CHEN S-C, NICHOLS PW, SKINNER DG, JONES PA AND COTE RJ. (1994). Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331, 1259 - 1264.
14. GAZZERI S, BRAMBILLA E, CARON DE FROMENTEL C, GOUYER V, MORO D, PERRON P, BERGER F AND BRAMBILLA C. (1994). p53 genetic abnormalities and myc activation in human lung carcinoma. Int. J. Cancer, 58, 24 - 32.
15. GRECO C, GANDOLFO GM, MATTEI F, GRADILONE A, ALVINO S, PASTORE LI, CASALE P, GRASSI A, CIANCIULLI AM AND AGLIANO AM. (1994). Detection of c-myb genetic alterations and mutant p53 serum protein in patients with benign and malignant colon lesions. Anticancer Res., 14, 1433 - 1440.
16. HARLOW E AND LANE D. (1988). Antibodies: A Laboratory Manual, pp. 53 - 287. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.
17. HASSAPOGLIDOU S, DIAMANDIS EP AND SUTHERLAND DJA. (1993). Quantification of p53 protein in tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene, 8, 1501 - 1509.
18. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49 53.
19. JOYPAUL BV, VOJTESEK B, NEWMAN EL, HOPWOOD D, GRANT A, LANE DP AND CUSCHIERI A. (1993). Enzyme-linked immunosorbent assay for p53 in gastrointestinal malignancy: comparison with immunohistochemistry. Histopathology, 23, 465 470.
20. KUERBITZ SJ, PLUNKETT BS, WALSH WV AND KASTAN MB. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 50, 379 384.
21. LAHDEAHO M-L, LEHTINEN T, AINE R, HAKALA T AND LEHTINEN M. (1994). Antibody response to adenovirus E1b-derived synthetic peptides and serum levels of p53 in patients with gastrointestinal and other malignant lymphomas. J. Med. Virol., 43, 393 - 396.
22. LEHTINEN T, AINE R, KELLOKUMPU-LEHTINEN P, HAKALA T AND LEHTINEN M. (1993). Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma. Acta Oncol., 32, 779 781.
23. LEVESQUE MA, KATSAROS D, YU H, ZOLA P, SISMONDI P, GIARDINA G AND DIAMANDIS EP. (1995a). Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer, 75, 1327 - 1338.
24. LEVESQUE MA, D'COSTA M, ANGELOPOULOU K AND DIAMANDIS EP. (1995b). Time-resolved immunofluorometric assay of p53 protein. Clin. Chem., 41, 1720 1729.
25. LEVESQUE MA, CLARK GM, YU H AND DIAMANDIS EP. (1995c). Imniunofluorometric analysis of p53 protein and prostate specific antigen in breast tumours and their association with other prognostic indicators. Br. J. Cancer, 72, 720 - 727.
26. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour suppressor gene. Nature, 351, 453 456.
27. LOHMANN D, PUTZ B, REICH U, BOHM J, PRAUER H AND HOFLER H. (1993). Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathologic data. Am. J. Pathol., 142, 907 915.
28. LOWE, SW, SCHMITT EM, SMITH SW, OSBORNE BA AND JACKS T. (1993). p53 is required for radiation induced apoptosis in mouse thymoeytes. Nature, 362, 847 - 849.
29. LUBIN R, ZALCMAN G, BOUCHET L, TREDANIEL J, LEGROS Y, CAZALS D, HIRSCH A AND SOUSSI T. (1995). Serum p53 antibodies as early markers of lung cancer. Nature Med., 1, 701 - 702.
30. LUO J-C, ZEHAB R, ANTTILA S, RIDANPAA M, HUSGAFVELPURSIAINEN K, VAINIO H, CARNEY W, DEVIVO I, MILLING C AND BRANDT-RAUF PW. (1994). Detection of serum p53 protein in lung cancer patients. J. Occup. Med., 36, 155 - 160.
31. LUO-J-C, NEUGUT AI, GARBOWSKI G, FORDE KA, TREAT M, SMITH W, CARNEY WP AND BRANDT-RAUF PW. (1995). Level of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett., 91, 235 240.
32. MAO L, HRUBAN RH, BOYLE JO, TOCKMAN M AND SIDRANSKY D. (1994). Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res., 54, 1634 1637.
33. MARCHETTI A, BUTTITTA F, MERLO G, DIELLA PELLEGRINI S, PEPE S, MACCHIARINI P, CHELLA A, ANGELETTI CA, CALLAHAN R, BISTOCCHI M AND SQUARTINI F. (1993). p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res., 53, 2846 2851.
34. MIDGLEY CA, FISHER CJ, BARTEK J, VOJTESEK B, LANE DP AND BARNES BM. (1992). Analysis of p53 expression in human tumors: an antibody raised against human p53 expression in Escherichia coli. J. Cell Sci., 101, 183 - 189.
35. MILLER CW, SIMON K, ASLO A, KOK K, YOKOTA J, BUYS CHC, TERADA M AND KOEFFLER HP. (1992). p53 mutations in human lung cancers. Cancer Res., 52, 1695 1698.
36. MITSUDOMI T, OYAMA T, KUSANO T, OSAKI T, NAKANISHI R AND SHIRAKUSA T. (1993a). Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl Cancer Inst., 85, 2018 2023.
37. MITSUDOMI T, LAM S, SHIRAKUSA T AND GAZDAR AF. (1993b). Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest, 104, 362 - 365.
38. NAHM MH AND HOFFMANN JW. (1990). Heteroantibody: phantom of the immunoassay. Clin. Chem., 36, 829.
39. PAPPOT H, FRANCIS D, BRUNNER N, GRONDAHL-HANSEN J AND OSTERLIND K. (1996). p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. Clin. Cancer Res., 2, 155 - 160.
40. PARTANEN P, KOSKINEN H, OKSA P, HEMMINKI K, CARNEY W, SMITH S AND BRANDT-RAUF P. (1995). Serum oncoproteins in asbestosis patients. Clin. Chem., 41, 1844 1847.
41. QUINLAN DC, DAVIDSON AG, SUMMERS CL, WARDEN WE AND DOSHI HM. (1992). Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52, 4828 4831.
42. REMVIKOS Y, TOMINAGA O, HAMMEL P, LAURENT-PUIG P, SALMAN RJ, DUTRILLAUX B AND THOMAS G. (1992). Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer, 66, 758 764.
43. ROSANELLI GP, WIRNSBERGER GH, PURSTNER P AND STEINDORFER P. (1993). DNA flow cytometry and immunohistochemical demonstration of mutant p53 protein versus TPS and mutant p53 protein serum levels in human breast cancer. Proc. Am. Assoc. Cancer Res., 34, 227.
44. RYBERG D, KURE E, LYSTAD S, SKAUG V, STANGELAND L, MERCY I, BORRESEN A-L AND HAUGEN A. (1994). p53 mutations in lung tumors: relationships to putative susceptibility markers for cancer. Cancer Res., 54, 1551 - 1555.
45. SCHLICHTHOLZ B, TREDANIEL J, LUBIN R, ZALCMAN G, HIRSCH A AND SOUSSI T. (1994). Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69, 809 816.
46. SMITH ML, CHEN I-T, ZHAN Q, BAE I, CHEN C-Y, GILMER TM, KASTAN MB, O'CONNOR PM AND FORNACE AJ JR. (1994). Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science, 266, 1376 - 1380.
47. SOUSSI T, LEGROS Y, KUBIN R, ORY K AND SCHLICHTHOLZ B, (1994). Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer, 57, 1 - 9.
48. SUZUKI H, TAKAHASHI T, KUROISHI T, SUYAMA M, ARIYOSHI Y, TAKAHASHI T AND UEDA R. (1992). p53 mutations in non-small cell lung cancer in Japan: associations between mutations and smoking. Cancer Res., 52, 734 736.
49. THOR AD, MOORE DH II, EDGERTON SM, KAWASAKI ES, REIHSAUS E, LYNCH HT, MARCUS JN, SCHWARTZ L, CHEN LC, MAYALL BH AND SMITH HS. (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst., 84, 845 855.
50. TRUMPER L, JUNG W, DAHL DIEHL V, GAUSE A AND PFREUNDSCHUH M. (1994). Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann. Oncol., 5(suppl.1), 93 96.
51. VOJTESEK B, BARTEK J, MIDGLEY CA AND LANE DP. (1992). An immunochemical analysis of human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151, 237 244.
52. VOJTESEK B, FISHER CJ, BARNES DM AND LANE DP. (1993). Comparison between p53 staining in tissue sections and p53 protein levels measured by an ELISA technique. Br. J. Cancer, 67, 1254 - 1258.
53. WALKER C, ROBERTSON LJ, MYSKOW MW, PENDLETON N AND DIXON GR. (1994). p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer, 70, 297 303.
54. WINTER SF, MINNA JD, JOHNSON BE, TAKAHASHI T, GAZDAR AF AND CARBONE DP. (1992). Development of antibodies against p53 in lung cancer patients appear to be dependent on the type of p53 mutation. Cancer Res., 52, 4168 - 4174.
55. WORLD HEALTH ORGANIZATION. (1982). The World Health Organization. Histological typing of lung tumors. Am. J. Clin. Pathol., 77, 123 136.
56. ZUSMAN I, ZUSMAN R, KOROL D, SANDLER B, BEN-HUR H, BASS D, MASHIAH A, LIFSHITZ-MERCER B, SMIRNOFF P AND GLICK J. (1995). Isolation of p53 protein from the serum of colon cancer and non-cancer patients. Oncol. Reports, 2, 679 683.
57. ZWEIG MH AND CAMPBELL G. (1993). Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem., 39, 561 - 577.